OSLO, Norway, Oct. 23, 2019 /PRNewswire/ -- Reference is
made to the stock exchange announcement on 18 October 2019 regarding the successful
completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company")
private placement of new shares (the "Private Placement"). The
Private Placement is divided into two tranches, as further
explained in the stock exchange announcement on 18 October 2019.
The share capital increase pertaining to the 5,511,946 new
shares, each with a nominal value of NOK
0.20, to be issued in tranche 1 of the Private Placement
(the "Tranche 1 Shares") has been registered in the Norwegian
Register of Business Enterprises (the "NRBE") on 23 October 2019, and the Company's share capital
has been increased with NOK
1,102,389.20 through the issuance of the Tranche 1 Shares.
The Tranche 1 Shares have been delivered to the investors by way of
borrowed shares on 22 October 2019
and the Tranche 1 Shares will be delivered to HealthCap VI L.P. to
settle the share loan pursuant to the share lending agreement
entered into on 16 October 2019.
Following registration of the share capital increase related to
the Tranche 1 Shares in the NRBE, the Company has an issued share
capital of NOK 13,228,672.60, divided
into 66,143,363 shares, each with a par value of NOK 0.20. Both the share capital increases
pertaining to the Private Placement have now been registered in the
NRBE.
For further information, please contact:
Malene Brondberg,
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
This information is subject to the disclose requirements
pursuant to the Continuing Obligations for companies listed on the
Oslo Stock Exchange section 3.2.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---tranche-1-share-capital-increase-registered,c2939409
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa---tranche-1-share-capital-increase-registered-300943861.html
SOURCE Nordic Nanovector